Results of a clinical study of the efficacy and safety of Panavir® in the treatment of keratoconjunctivitis of adenovirus etiology

Objective: to analyze the efficacy, safety and tolerability of Panavir® (eye drops 0.004%) in the treatment of keratoconjunctivitis of adenovirus etiology. Material and methods. 216 patients with acute keratoconjunctivitis of adenovirus etiology participated. Group 1 patients received Panavir® 0.004%, group 2 patients received Ophthalmoferon® (interferon alfa-2b). The study included 5 visits. Results. There was a significant decrease in the number of patients with the studied symptoms (conjunctival follicles and hemorrhages, conjunctival edema and hyperemia, subepithelial infiltrates, itching, foreign body sensation, lacrimation and eyelid edema) by day 10 in both groups (p